Gemtesa (vibegron) is not currently available as a generic medication. It is an on-demand treatment for overactive bladder (OOB) with urinary urgency, frequency, and incontinence, approved by the U.S. Food and Drug Administration (FDA) in 2020 [1].
When does Gemtesa's patent protection end?
The exact expiration dates for Gemtesa's patents are not publicly available. However, patents for brand-name drugs typically provide market exclusivity for a significant period, often around 20 years from the filing date [2]. Information on specific patent litigation and exclusivity periods for drugs like Gemtesa can often be found through resources that track pharmaceutical patents [3].
Can biosimilars or generics be made for Gemtesa?
Generic versions of Gemtesa cannot be legally manufactured or sold until its patents expire and any other forms of market exclusivity, such as those granted by regulatory bodies, have concluded. For small molecule drugs like vibegron, these are typically referred to as generics, not biosimilars, which are for biologic drugs [4].
What is Gemtesa used for?
Gemtesa is prescribed to treat adults with overactive bladder (OOB). OOB is characterized by symptoms such as a sudden, strong urge to urinate (urgency), needing to urinate more often than usual (frequency), and sometimes experiencing involuntary leakage of urine (incontinence) [1].
How does Gemtesa work?
Vibegron, the active ingredient in Gemtesa, is a beta-3 adrenergic agonist. It works by relaxing the detrusor muscle, which is the muscle in the bladder wall. By relaxing this muscle, it increases bladder capacity and reduces the involuntary contractions that cause urgency and frequency in OOB [1].